Separation of nuclear isomers for cancer therapeutic radionuclides based on nuclear decay after-effects

Rupali Bhardwaj, Astrid van der Meer, Satyen Das, M de Bruin, Jorge Gascon, Bert Wolterbeek, Antonia Denkova, Pablo Serra Crespo

Research output: Contribution to journalArticleScientificpeer-review

9 Citations (Scopus)
42 Downloads (Pure)

Abstract

177Lu has sprung as a promising radionuclide for targeted therapy. The low soft tissue penetration of its β− emission results in very efficient energy deposition in small-size tumours. Because of this, 177Lu is used in the treatment of neuroendocrine tumours and is also clinically approved for prostate cancer therapy. In this work, we report a separation method that achieves the challenging separation of the physically and chemically identical nuclear isomers, 177mLu and 177Lu. The separation method combines the nuclear after-effects of the nuclear decay, the use of a very stable chemical complex and a chromatographic separation. Based on this separation concept, a new type of radionuclide generator has been devised, in which the parent and the daughter radionuclides are the same elements. The 177mLu/177Lu radionuclide generator provides a new production route for the therapeutic radionuclide 177Lu and can bring significant growth in the research and development of 177Lu based pharmaceuticals.
Original languageEnglish
Article number44242
JournalScientific Reports
Volume7
DOIs
Publication statusPublished - 13 Mar 2017

Keywords

  • Medicinal chemistry
  • Nuclear chemistry
  • OA-Fund TU Delft

Fingerprint Dive into the research topics of 'Separation of nuclear isomers for cancer therapeutic radionuclides based on nuclear decay after-effects'. Together they form a unique fingerprint.

Cite this